Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Orexigen granted new patent for obesity drug
The patent broadly covers methods of treating obesity with combinations of bupropion and naltrexone, the two active agents in Contrave. It is a companion to the Weber/Cowley composition
The patent broadly covers methods of treating obesity with combinations of bupropion and naltrexone, the two active agents in Contrave. It is a companion to the Weber/Cowley composition
As a result of these actions, Cigna expects to incur approximately $30-40 million, after tax, in cost reduction charges in the fourth quarter of 2008. The job eliminations
As part of this collaboration, PPD will be providing Merck with assay development and immunogenicity testing services to support Merck’s vaccine portfolio over a period of five years.
Dr Kirkpatrick has an extensive background in targeted small molecule cancer drug development, and has brought three agents from bench to bedside. Co-founder of ProlX Pharmaceuticals, Dr Kirkpatrick
This new center has 24 treatment stations and is currently caring for approximately 145 dialysis patients. The company is considering adding six more stations to the facility, which
Prism intends to submit a supplemental new drug application (NDA) for the premixed configurations which will form the focus of the commercial launch of Nexterone as a complete
Mr Elstein has been a member of Teva’s senior management since 2005. Mr Elstein most recently held the position of executive vice president of global pharmaceutical resources. Prior
Prior to joining Oni BioPharma, Dr Handfield was a tenured faculty member at the Center for Molecular Microbiology and Department of Oral Biology, University of Florida. Martin has
“We are delighted and grateful to have the continuing support of GCIC,” said Jake Orville, president and chief executive of Prognostix. “GCIC’s first grant enabled Prognostix to make
The process has also included a review of the potential out-licensing of assets, asset divestiture, or liquidation of the company. Vasogen also reported that during this process it